Last checked at 4 Dec 2012 12:40
4 December 2012
Allergy Therapeutics plc
("Allergy Therapeutics" or "the Company")
Exercise of Options
Allergy Therapeutics plc (AIM: AGY), the fully integrated speciality pharmaceutical company specialising in allergy vaccines, announces it has made an application to the London Stock Exchange for 30,000 ordinary shares of 0.1p each to be admitted to trading on AIM. Dealing is expected to commence in these shares on 7 December 2012. The ordinary shares have been allotted pursuant to the exercise of options and will rank pari passu in all respects with the existing ordinary share capital of the Company. The total number of shares in issue (inclusive of the above issue) is 408,342,981
Ordinary shares of 0.1p each.
For further information
Allergy Therapeutics | +44 (0) 1903 845 820 |
Manuel Llobet, Chief Executive Officer | |
Ian Postlethwaite, Finance Director | |
www.allergytherapeutics.com | |
Nomura Code Securities | +44 (0) 207 776 1200 |
Juliet Thompson / Clare Terlouw | |
FTI Consulting | +44 (0) 207 831 3113 |
Simon Conway / Susan Stuart / Victoria Foster-Mitchell |